Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2017

18.05.2017 | Clinical trial

Effect of age on breast cancer screening using tomosynthesis in combination with digital mammography

verfasst von: Elizabeth A. Rafferty, Stephen L. Rose, Dave P. Miller, Melissa A. Durand, Emily F. Conant, Debra S. Copit, Sarah M. Friedewald, Donna M. Plecha, Ingrid L. Ott, Mary K. Hayes, Kara L. Carlson, Thomas M. Cink, Lora D. Barke, Linda N. Greer, Loren T. Niklason

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine the effect of tomosynthesis imaging as a function of age for breast cancer screening.

Methods

Screening performance metrics from 13 institutions were examined for 12 months prior to introduction of tomosynthesis (period 1) and compared to those after introduction of tomosynthesis (period 2, range 3–22 months). Screening metrics for women ages 40–49, 50–59, 60–69, and 70+ , included rates per 1000 screens for recalls, biopsies, cancers, and invasive cancers detected.

Results

Performance parameters were compared for women screened with digital mammography alone (n = 278,908) and digital mammography + tomosynthesis (n = 173,414). Addition of tomosynthesis to digital mammography produced significant reductions in recall rates for all age groups and significant increases in cancer detection rates for women 40–69. Largest recall rate reduction with tomosynthesis was for women 40–49, decreasing from 137 (95% CI 117–156) to 115 (95% CI 95–135); difference, −22 (95% CI −26 to −18; P < .001). Simultaneous increase in invasive cancer detection rate for women 40–49 from 1.6 (95% CI 1.2–1.9) to 2.7 (95% CI 2.2–3.1) with tomosynthesis (difference, 1.1; 95% CI 0.6–1.6; P < .001) was observed.

Conclusions

Addition of tomosynthesis to digital mammography increased invasive cancer detection rates for women 40–69 and decreased recall rates for all age groups with largest performance gains seen in women 40–49. The similar performance seen with tomosynthesis screening for women in their 40s compared to digital mammography for women in their 50s argues strongly for commencement of mammography screening at age 40 using tomosynthesis.
Literatur
1.
Zurück zum Zitat Tabár L, Vitak B, Chen TH et al (2011) Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 260(3):658–663CrossRefPubMed Tabár L, Vitak B, Chen TH et al (2011) Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 260(3):658–663CrossRefPubMed
2.
Zurück zum Zitat U.S. Preventive Services Task Force (2009) Screening for breast cancer: U.S. Preventive services task force recommendation statement. Ann Intern Med 151:716–726CrossRef U.S. Preventive Services Task Force (2009) Screening for breast cancer: U.S. Preventive services task force recommendation statement. Ann Intern Med 151:716–726CrossRef
3.
Zurück zum Zitat Lauby-Secretan B, Scoccianti C, Loomis D et al (2015) Breast-cancer screening—viewpoint of the IARC Working Group. N Engl J Med 372(24):2353–2358CrossRefPubMed Lauby-Secretan B, Scoccianti C, Loomis D et al (2015) Breast-cancer screening—viewpoint of the IARC Working Group. N Engl J Med 372(24):2353–2358CrossRefPubMed
4.
Zurück zum Zitat Siu AL, US Preventative Task Force (2016) Screening for breast cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 164(4):279–296CrossRefPubMed Siu AL, US Preventative Task Force (2016) Screening for breast cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 164(4):279–296CrossRefPubMed
5.
Zurück zum Zitat Oeffinger K, Fontham E, Etzioni R et al (2015) Breast cancer screening for women at average risk: 2015 Guideline update from the American Cancer Society. JAMA 314:1599–1614CrossRefPubMedPubMedCentral Oeffinger K, Fontham E, Etzioni R et al (2015) Breast cancer screening for women at average risk: 2015 Guideline update from the American Cancer Society. JAMA 314:1599–1614CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Skaane P, Bandos AI, Gullien R et al (2013) Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program. Radiology 267(1):47–56CrossRefPubMed Skaane P, Bandos AI, Gullien R et al (2013) Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program. Radiology 267(1):47–56CrossRefPubMed
7.
Zurück zum Zitat Ciatto S, Houssami N, Bernardi D et al (2013) Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study. Lancet Oncol 14(7):583–589CrossRefPubMed Ciatto S, Houssami N, Bernardi D et al (2013) Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study. Lancet Oncol 14(7):583–589CrossRefPubMed
8.
Zurück zum Zitat Rose SL, Tidwell AL, Bujnoch LJ, Kushwaha AC, Nordmann AS, Sexton R Jr (2013) Implementation of breast tomosynthesis in a routine screening practice: an observational study. AJR Am J Roentgenol 200(6):1401–1408CrossRefPubMed Rose SL, Tidwell AL, Bujnoch LJ, Kushwaha AC, Nordmann AS, Sexton R Jr (2013) Implementation of breast tomosynthesis in a routine screening practice: an observational study. AJR Am J Roentgenol 200(6):1401–1408CrossRefPubMed
9.
Zurück zum Zitat Haas BM, Kalra V, Geisel J, Raghu M, Durand M, Philpotts LE (2013) Comparison of tomosynthesis plus digital mammography and digital mammography alone for breast cancer screening. Radiology 269(3):694–700CrossRefPubMed Haas BM, Kalra V, Geisel J, Raghu M, Durand M, Philpotts LE (2013) Comparison of tomosynthesis plus digital mammography and digital mammography alone for breast cancer screening. Radiology 269(3):694–700CrossRefPubMed
10.
Zurück zum Zitat McCarthy AM, Kontos D, Synnestvedt M et al (2014) Screening outcomes following implementation of digital breast tomosynthesis in a general-population screening program. J Natl Cancer Inst 106(11):dju316CrossRefPubMedPubMedCentral McCarthy AM, Kontos D, Synnestvedt M et al (2014) Screening outcomes following implementation of digital breast tomosynthesis in a general-population screening program. J Natl Cancer Inst 106(11):dju316CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Lång K, Andersson I, Rosso A, Tingberg A, Timberg P, Zackrisson S (2016) Performance of one-view breast tomosynthesis as a stand-alone breast cancer screening modality: results from the malmö breast tomosynthesis screening trial, a population-based study. Eur Radiol 26(1):184–190CrossRefPubMed Lång K, Andersson I, Rosso A, Tingberg A, Timberg P, Zackrisson S (2016) Performance of one-view breast tomosynthesis as a stand-alone breast cancer screening modality: results from the malmö breast tomosynthesis screening trial, a population-based study. Eur Radiol 26(1):184–190CrossRefPubMed
12.
Zurück zum Zitat Friedewald SM, Rafferty EA, Rose SL et al (2014) Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA 311(24):2499–2507CrossRefPubMed Friedewald SM, Rafferty EA, Rose SL et al (2014) Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA 311(24):2499–2507CrossRefPubMed
13.
Zurück zum Zitat Rafferty EA, Durand MA, Conant EF et al (2016) Breast cancer screening using tomosynthesis and digital mammography in dense and non-dense breasts. JAMA 315(16):1784–1786CrossRefPubMed Rafferty EA, Durand MA, Conant EF et al (2016) Breast cancer screening using tomosynthesis and digital mammography in dense and non-dense breasts. JAMA 315(16):1784–1786CrossRefPubMed
14.
Zurück zum Zitat Broeders M, Moss S, Nystrom L, EUROSCREEN Working Group et al (2012) The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen 19(suppl 1):14–25CrossRefPubMed Broeders M, Moss S, Nystrom L, EUROSCREEN Working Group et al (2012) The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen 19(suppl 1):14–25CrossRefPubMed
15.
Zurück zum Zitat Gotzche PC, Jorgensen KJ (2013) Screening for breast cancer with mammography. Cochrane Database Syst Rev 6:CD001877 Gotzche PC, Jorgensen KJ (2013) Screening for breast cancer with mammography. Cochrane Database Syst Rev 6:CD001877
16.
Zurück zum Zitat Berry DA, Cronin KA, Plevritis SK, Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353(17):1784–1792CrossRefPubMed Berry DA, Cronin KA, Plevritis SK, Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353(17):1784–1792CrossRefPubMed
Metadaten
Titel
Effect of age on breast cancer screening using tomosynthesis in combination with digital mammography
verfasst von
Elizabeth A. Rafferty
Stephen L. Rose
Dave P. Miller
Melissa A. Durand
Emily F. Conant
Debra S. Copit
Sarah M. Friedewald
Donna M. Plecha
Ingrid L. Ott
Mary K. Hayes
Kara L. Carlson
Thomas M. Cink
Lora D. Barke
Linda N. Greer
Loren T. Niklason
Publikationsdatum
18.05.2017
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2017
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4299-0

Weitere Artikel der Ausgabe 3/2017

Breast Cancer Research and Treatment 3/2017 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.